Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy
Open Access
- 17 April 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (4) , 372
Abstract
Repurposing of approved non-antitumor drugs represents a promising and affordable strategy that may help to increase the repertoire of effective anticancer drugs. Benzimidazole-based anthelmintics are antiparasitic drugs commonly employed both in human and veterinary medicine. Benzimidazole compounds are being considered for drug repurposing due to antitumor activities displayed by some members of the family. In this study, we explored the effects of a large series of benzimidazole-based anthelmintics (and some enantiomerically pure forms of those containing a stereogenic center) on the viability of different tumor cell lines derived from paraganglioma, pancreatic and colorectal cancer. Flubendazole, parbendazole, oxibendazole, mebendazole, albendazole and fenbendazole showed the most consistent antiproliferative effects, displaying IC50 values in the low micromolar range, or even in the nanomolar range. In silico evaluation of their physicochemical, pharmacokinetics and medicinal chemistry properties also provided useful information related to the chemical structures and potential of these compounds. Furthermore, in view of the potential repurposing of these drugs in cancer therapy and considering that pharmaceutically active compounds may have different mechanisms of action, we performed an in silico target prediction to assess the polypharmacology of these benzimidazoles, which highlighted previously unknown cancer-relevant molecular targets.Keywords
This publication has 44 references indexed in Scilit:
- Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effectsLife Sciences, 2020
- Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive SystemInternational Journal of Molecular Sciences, 2020
- New drugs are not enough‑drug repositioning in oncology: An updateInternational Journal of Oncology, 2020
- The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing DrugsImmune Network, 2020
- Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costsClinical and Translational Medicine, 2018
- Flubendazole induces mitotic catastrophe and apoptosis in melanoma cellsToxicology in Vitro, 2018
- Drug repurposing in oncology—patient and health systems opportunitiesNature Reviews Clinical Oncology, 2015
- Potential Anti-cancer Drugs Commonly Used for Other IndicationsCurrent Cancer Drug Targets, 2015
- Drug Resistance in Cancer: An OverviewCancers, 2014
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012